- Home
- OGEN vs ALLR Comparison
OGEN vs ALLR Comparison
Compare OGEN & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- ALLR
- Stock Information
- Founded
- OGEN 1996
- ALLR 2004
- Country
- OGEN United States
- ALLR United States
- Employees
- OGEN N/A
- ALLR N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- ALLR Health Care
- Exchange
- OGEN Nasdaq
- ALLR Nasdaq
- Market Cap
- OGEN 4.5M
- ALLR 4.5M
- IPO Year
- OGEN N/A
- ALLR N/A
- Fundamental
- Price
- OGEN $0.34
- ALLR $1.06
- Analyst Decision
- OGEN
- ALLR
- Analyst Count
- OGEN 0
- ALLR 0
- Target Price
- OGEN N/A
- ALLR N/A
- AVG Volume (30 Days)
- OGEN 269.0K
- ALLR 218.5K
- Earning Date
- OGEN 11-13-2024
- ALLR 11-14-2024
- Dividend Yield
- OGEN N/A
- ALLR N/A
- EPS Growth
- OGEN N/A
- ALLR N/A
- EPS
- OGEN N/A
- ALLR N/A
- Revenue
- OGEN N/A
- ALLR N/A
- Revenue This Year
- OGEN N/A
- ALLR N/A
- Revenue Next Year
- OGEN N/A
- ALLR N/A
- P/E Ratio
- OGEN N/A
- ALLR N/A
- Revenue Growth
- OGEN N/A
- ALLR N/A
- 52 Week Low
- OGEN $0.25
- ALLR $0.90
- 52 Week High
- OGEN $7.74
- ALLR $378.00
- Technical
- Relative Strength Index (RSI)
- OGEN 49.33
- ALLR 39.84
- Support Level
- OGEN $0.32
- ALLR $0.90
- Resistance Level
- OGEN $0.38
- ALLR $1.14
- Average True Range (ATR)
- OGEN 0.03
- ALLR 0.08
- MACD
- OGEN 0.00
- ALLR 0.02
- Stochastic Oscillator
- OGEN 38.89
- ALLR 66.67
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.